MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.contraception.2025.111016

Медицинская библиотека · Contraception · 2025

Vaginal contraception with NuvaRing decreases symptoms and uterine features of adenomyosis: A prospective evaluation.

Xholli Anjeza, Oppedisano Francesca, Ferraro Mattia Francesco, Perugi Isabella, Londero Ambrogio P, Cagnacci Angelo

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

We aimed to assess the effects of contraception with NuvaRing on ultrasound signs and symptoms of women with adenomyosis.

STUDY

DESIGN

We conducted a prospective self-controlled observational study on women with adenomyosis who required contraception with NuvaRing. Exclusion criteria were actual use or contraindications to hormonal contraception. NuvaRing was administered in a continuous regimen, one ring every 3 weeks without hormone-free intervals, to avoid menses. Adenomyosis, suggested by clinical signs, was confirmed by ultrasonography. Before and after 6 months of NuvaRing, we evaluated uterine volume, direct and indirect ultrasound signs of adenomyosis, and the severity of menstrual, intermenstrual pain, and pain during intercourse, by a 10-cm visual analog scale (VAS).

RESULT(S): This study included 42 women, 30.0 ± 4.5 years old, with a BMI of 22.8 ± 1.8 kg/m². All were nulliparous except one. Following 6 months of NuvaRing, uterine volume decreased of 14.4 ± 13.5% (p = 0.001). A similar decrease was observed in six women switching from dienogest. Direct ultrasound signs of adenomyosis per patient (total signs/n women) decreased from 0.5 (range 0-3) to 0.08 (range 0-2) (p = 0.003), and indirect signs, from 2.8 (range 1-5) to 1.5 (range 0-5) (p = 0.001). The VAS for menstrual pain decreased from 8.3 ± 1.2 to 3.9 ± 2.5 (p = 0.001), for intermenstrual pain from 6.6 ± 1.4 to 2.9 ± 1.7 (p = 0.001), and for pain during intercourse from 7.0 ± 1.4 to 2.9 ± 1.7 (p = 0.001). The decrease of menstrual pain was significantly associated with the reduction of uterine volume (p = 0.003).

CONCLUSION(S): Our findings demonstrate that contraception with NuvaRing is a viable contraceptive option for women with adenomyosis.

IMPLICATIONS: In women with adenomyosis contraception with NuvaRing is useful and can be proposed because it reduces the clinical signs and the uterine ultrasound features of adenomyosis.

Для цитирования: Xholli Anjeza, Oppedisano Francesca, Ferraro Mattia Francesco, Perugi Isabella, Londero Ambrogio P, Cagnacci Angelo. Vaginal contraception with NuvaRing decreases symptoms and uterine features of adenomyosis: A prospective evaluation.. Contraception. 2025. DOI: 10.1016/j.contraception.2025.111016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.